Pfizer says 2024 profits will fall far below expectations; Vertex non-opioid drug reduces chronic nerve pain in mid-stage study

Taking stock of the drug industry, from the lab to the medicine chest

December 13, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mark Lennihan/AP STAT+ | Pfizer says 2024 profits will fall far below expectations The company said layoffs and other cost-cutting measures would save $4 billion, $500 million more than it had previously stated. By Matthew Herper STAT+ | Vertex non-opioid drug reduces chronic nerve pain in mid-stage study The results support the biotech company's efforts to develop an effective painkiller without the addictive potential of opioids. By Adam Feuerstein and Jonathan Wosen STAT+ | Maze CEO 'personally disappointed' in Sanofi decision to terminate partnership The French pharma giant terminated the deal after the U.S. Federal Trade Commission said it would move to block it. By Adam Feuerstein GABRIEL MONNET/AFP via Getty Images STAT+ | Could sickle cell someday be treated not with CRISPR, but with a pill? Even with gene therapies now available, researchers say the world need simpler drugs for sickle cell. Novartis may have found one. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser